We investigated the roles played by the cysteine proteases cathepsin B and cathepsin L (brucipain) in the pathogenesis of Trypansoma brucei brucei in both an in vivo mouse model and an in vitro model of the blood–brain barrier. Doxycycline induction of RNAi targeting cathepsin B led to parasite clearance from the bloodstream and prevent a lethal infection in the mice. In contrast, all mice infected with T. brucei containing the uninduced Trypanosoma brucei cathepsin B (TbCatB) RNA construct died by day 13. Induction of RNAi against brucipain did not cure mice from infection; however, 50% of these mice survived 60 days longer than uninduced controls. The ability of T. b. brucei to cross an in vitro model of the human blood–brain barrier was also reduced by brucipain RNAi induction. Taken together, the data suggest that while TbCatB is the more likely target for the development of new chemotherapy, a possible role for brucipain is in facilitating parasite entry into the brain.
References
[1]
Scory S, Caffrey CR, Stierhof YD, Ruppel A, Steverding D (1999) Trypanosoma brucei: killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-phe-ala-CHN2. Exp Parasitol 91: 327–333. doi: 10.1006/expr.1998.4381
[2]
Mackey ZB, O'Brien TC, Greenbaum DC, Blank RB, McKerrow JH (2004) A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei. J Biol Chem 279: 48426–48433. doi: 10.1074/jbc.M402470200
[3]
Troeberg L, Morty RE, Pike RN, Lonsdale-Eccles JD, Palmer JT, et al. (1999) Cysteine proteinase inhibitors kill cultured bloodstream forms of Trypanosoma brucei brucei. Exp Parasitol 91: 349–355. doi: 10.1006/expr.1998.4386
[4]
Triggs VP, Bangs JD (2003) Glycosylphosphatidylinositol-dependent protein trafficking in bloodstream stage Trypanosoma brucei. Eukaryot Cell 2: 76–83. doi: 10.1128/EC.2.1.76-83.2003
[5]
Nikolskaia OV, de ALAP, Kim YV, Lonsdale-Eccles JD, Fukuma T, et al. (2006) Blood-brain barrier traversal by African trypanosomes requires calcium signaling induced by parasite cysteine protease. J Clin Invest 116: 2739–2747. doi: 10.1172/JCI27798
[6]
Lecordier L, Walgraffe D, Devaux S, Poelvoorde P, Pays E, et al. (2005) Trypanosoma brucei RNA interference in the mammalian host. Mol Biochem Parasitol 140: 127–131. doi: 10.1016/j.molbiopara.2004.12.009
[7]
Hill KL, Hutchings NR, Russell DG, Donelson JE (1999) A novel protein targeting domain directs proteins to the anterior cytoplasmic face of the flagellar pocket in African trypanosomes. J Cell Sci 112 Pt 18: 3091–3101.
[8]
Wirtz E, Leal S, Ochatt C, Cross GA (1999) A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol Biochem Parasitol 99: 89–101. doi: 10.1016/S0166-6851(99)00002-X
[9]
Stins MF, Prasadarao NV, Zhou J, Arditi M, Kim KS (1997) Bovine brain microvascular endothelial cells transfected with SV40-large T antigen: development of an immortalized cell line to study pathophysiology of CNS disease. In Vitro Cell Dev Biol Anim 33: 243–247. doi: 10.1007/s11626-997-0042-1
[10]
Stins MF, Gilles F, Kim KS (1997) Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol 76: 81–90. doi: 10.1016/S0165-5728(97)00036-2
[11]
Grab DJ, Nikolskaia O, Kim YV, Lonsdale-Eccles JD, Ito S, et al. (2004) African trypanosome interactions with an in vitro model of the human blood-brain barrier. J Parasitol 90: 970–979. doi: 10.1645/GE-287R
[12]
Hamadien M, Bakhiet M, Harris RA (2000) Interferon-gamma induces secretion of trypanosome lymphocyte triggering factor via tyrosine protein kinases. Parasitology 120(Pt 3): 281–287. doi: 10.1017/S0031182099005521
[13]
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(？Delta Delta C(T)) Method. Methods 25: 402–408. doi: 10.1006/meth.2001.1262
[14]
Caffrey CR, Hansell E, Lucas KD, Brinen LS, Alvarez Hernandez A, et al. (2001) Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. Mol Biochem Parasitol 118: 61–73. doi: 10.1016/S0166-6851(01)00368-1
[15]
Bogyo M, Verhelst S, Bellingard-Dubouchaud V, Toba S, Greenbaum D (2000) Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem Biol 7: 27–38. doi: 10.1016/S1074-5521(00)00061-2
[16]
Abdulla MH, Lim KC, Sajid M, McKerrow JH, Caffrey CR (2007) Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med 4: e14. doi:10.1371/journal.pmed.0040014. doi: 10.1371/journal.pmed.0040014
[17]
Renslo AR, McKerrow JH (2006) Drug discovery and development for neglected parasitic diseases. Nat Chem Biol 2: 701–710. doi: 10.1038/nchembio837
